Frontal fibrosing alopecia. Other cicatricial alopecia
Conditions
Interventions
Intervention 1: The first intervention group will receive 20 mg oral isotretinoin daily in the form of 20 mg capsules(made by pharmaceutical Zahravi Co.) with lunch meal for 3 months. Intervention 2:
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with facial papules diagnosed on the basis of clinicopathological evidence. (Evidence of inflammation and fibrosis seen in papules).
Exclusion criteria
Exclusion criteria: Pregnant or intended to be pregnant patients Lactating patients Patients with a history of allergy to retinoid compounds Known liver or kidney disease or abnormalities in related blood tests (leukopenia, moderate to severe hypercholesterolemia, hypertriglyceridemia, hypothyroidism, liver and kidney dysfunction) Patients with a history of pseudotumor cerebri Patients with a history of suicidal ideation Patients taking drugs that interact with isotretinoin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recovery score based on Global Aesthetic Improvement Scale. Timepoint: Before the start of the study and 1 , 2 , 3 months after the start of treatment. Method of measurement: Grading the scale of global aesthetics based on observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahsa Bahraminejad
Esfahan University of Medical Sciences
Outcome results
None listed